Novel antidepressant strategies to optimize outcome.
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D005473:Fluoxetine / Q000627:therapeutic use; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use; D009638:Norepinephrine / Q000037:antagonists & inhibitors; D010555:Personality Inventory / Q000706:statistics & numerical data; D000077593:Reboxetine; D012720:Severity of Illness Index; D012917:Social Adjustment; D016896:Treatment Outcome
D018759:Adrenergic Uptake Inhibitors; D000928:Antidepressive Agents; D009025:Morpholines; D005473:Fluoxetine; D000077593:Reboxetine; D009638:Norepinephrine